LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article: Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials.

    Bradley, David J / Bradley, Elizabeth A / Baughman, Kenneth L / Berger, Ronald D / Calkins, Hugh / Goodman, Steven N / Kass, David A / Powe, Neil R

    JAMA

    2002  Volume 289, Issue 6, Page(s) 730–740

    Abstract: ... patients and 3.5% for controls. Cardiac resynchronization also reduced heart failure hospitalization by 29 ... heart failure. Cardiac resynchronization also reduces heart failure hospitalization and shows a trend ... death from progressive heart failure by 51% relative to controls (odds ratio [OR], 0.49; 95 ...

    Abstract Context: Progressive heart failure is the most common mechanism of death among patients with advanced heart failure. Cardiac resynchronization, a pacemaker-based therapy for heart failure, enhances cardiac performance and quality of life, but its effect on mortality is uncertain.
    Objective: To determine whether cardiac resynchronization reduces mortality from progressive heart failure.
    Data sources: MEDLINE (1966-2002), EMBASE (1980-2002), the Cochrane Controlled Trials Register (Second Quarter, 2002), The National Institutes of Health ClinicalTrials.gov database, the US Food and Drug Administration Web site, and reports presented at scientific meetings (1994-2002). Search terms included pacemaker, pacing, heart failure, dual-site, multisite, biventricular, resynchronization, and left ventricular preexcitation.
    Study selection: Eligible studies were randomized controlled trials of cardiac resynchronization for the treatment of chronic symptomatic left ventricular dysfunction. Eligible studies reported death, hospitalization for heart failure, or ventricular arrhythmia as outcomes. Of the 6883 potentially relevant reports initially identified, 11 reports of 4 randomized trials with 1634 total patients were included in the meta-analysis.
    Data extraction: Trial reports were reviewed independently by 2 investigators in an unblinded standardized manner.
    Data synthesis: Follow-up in the included trials ranged from 3 to 6 months. Pooled data from the 4 selected studies showed that cardiac resynchronization reduced death from progressive heart failure by 51% relative to controls (odds ratio [OR], 0.49; 95% confidence interval [CI], 0.25-0.93). Progressive heart failure mortality was 1.7% for cardiac resynchronization patients and 3.5% for controls. Cardiac resynchronization also reduced heart failure hospitalization by 29% (OR, 0.71; 95% CI, 0.53-0.96) and showed a trend toward reducing all-cause mortality (OR, 0.77; 95% CI, 0.51-1.18). Cardiac resynchronization was not associated with a statistically significant effect on non-heart failure mortality (OR, 1.15; 95% CI, 0.65-2.02). Among patients with implantable cardioverter defibrillators, cardiac resynchronization had no clear impact on ventricular tachycardia or ventricular fibrillation (OR, 0.92; 95% CI, 0.67-1.27).
    Conclusions: Cardiac resynchronization reduces mortality from progressive heart failure in patients with symptomatic left ventricular dysfunction. This finding suggests that cardiac resynchronization may have a substantial impact on the most common mechanism of death among patients with advanced heart failure. Cardiac resynchronization also reduces heart failure hospitalization and shows a trend toward reducing all-cause mortality.
    MeSH term(s) Cardiac Pacing, Artificial ; Defibrillators, Implantable ; Heart Failure/mortality ; Heart Failure/therapy ; Humans ; Pacemaker, Artificial ; Randomized Controlled Trials as Topic ; Survival Analysis ; Ventricular Dysfunction, Left/therapy
    Language English
    Publishing date 2002-08-23
    Publishing country United States
    Document type Journal Article ; Meta-Analysis
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0098-7484 ; 0254-9077 ; 0002-9955
    ISSN (online) 1538-3598
    ISSN 0098-7484 ; 0254-9077 ; 0002-9955
    DOI 10.1001/jama.289.6.730
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Right ventricular lead location and outcomes among patients with cardiac resynchronization therapy: A meta-analysis.

    Ali-Ahmed, Fatima / Dalgaard, Frederik / Allen Lapointe, Nancy M / Kosinski, Andrzej S / Blumer, Vanessa / Morin, Daniel P / Sanders, Gillian D / Al-Khatib, Sana M

    Progress in cardiovascular diseases

    2021  Volume 66, Page(s) 53–60

    Abstract: ... review and meta-analysis of randomized controlled trials and prospective observational studies comparing ... Background: Cardiac resynchronization therapy (CRT) has been demonstrated to improve heart failure ... of death and first HFH hospitalization, change in LVEF, New York Heart Association (NYHA) class improvement ...

    Abstract Background: Cardiac resynchronization therapy (CRT) has been demonstrated to improve heart failure (HF) symptoms, reverse LV remodeling, and reduce mortality and HF hospitalization (HFH) in patients with a reduced left ventricular (LV) ejection fraction (LVEF). Prior studies examining outcomes based on right ventricular (RV) lead position among CRT patients have provided mixed results. We performed a systematic review and meta-analysis of randomized controlled trials and prospective observational studies comparing RV apical (RVA) and non-apical (RVNA) lead position in CRT.
    Methods: Our meta-analysis was constructed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for systematic reviews and meta-analyses. We searched EMBASE and MEDLINE. Eligible studies reported on at least one of the following outcomes of interest: all-cause mortality, the composite endpoint of death and first HFH hospitalization, change in LVEF, New York Heart Association (NYHA) class improvement, and change in LV end systolic volume (LVESV). We performed meta-analysis summaries using a DerSimonian-Laird random-effects model and conservatively used the Knapp-Hartung approach to adjust the standard errors of the estimated model coefficients.
    Results: We included nine studies representing a total of 1832 patients. Of those, 1318 (72%) patients had RVA lead placement and 514 (28%) had RVNA lead placement. The mean age of patients was 65.5 ± 4.4 years, and they were predominantly men (69%-97%). There was no statistically significant difference in all-cause mortality by RVA vs. RVNA (OR = 0.77, 95% CI 0.32-1.89; I
    Conclusion: This meta-analysis shows that in CRT pacing, RV lead position does not appear to be associated with clinical outcomes or LV reverse remodeling. Further studies should focus on the relationship of RV lead vis-à-vis LV lead location, and its clinical importance.
    MeSH term(s) Aged ; Cardiac Resynchronization Therapy/adverse effects ; Cardiac Resynchronization Therapy/mortality ; Cardiac Resynchronization Therapy Devices ; Equipment Design ; Female ; Heart Failure/diagnosis ; Heart Failure/mortality ; Heart Failure/physiopathology ; Heart Failure/therapy ; Humans ; Male ; Middle Aged ; Recovery of Function ; Stroke Volume ; Treatment Outcome ; Ventricular Function, Left ; Ventricular Function, Right ; Ventricular Remodeling
    Language English
    Publishing date 2021-04-20
    Publishing country United States
    Document type Journal Article ; Meta-Analysis ; Research Support, N.I.H., Extramural ; Systematic Review
    ZDB-ID 209312-1
    ISSN 1873-1740 ; 1532-8643 ; 0033-0620
    ISSN (online) 1873-1740 ; 1532-8643
    ISSN 0033-0620
    DOI 10.1016/j.pcad.2021.04.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Influence of diabetes on cardiac resynchronization therapy in heart failure patients: a meta-analysis.

    Sun, Hui / Guan, Yuqing / Wang, Lei / Zhao, Yong / Lv, Hong / Bi, Xiuping / Wang, Huating / Zhang, Xuejing / Liu, Li / Wei, Min / Song, Hui / Su, Guohai

    BMC cardiovascular disorders

    2015  Volume 15, Page(s) 25

    Abstract: ... from randomized controlled trials (RCTs) of the long-term outcome of cardiac resynchronization therapy for heart failure in diabetic ... of randomized controlled trials of Cardiac resynchronization for chronic symptomatic left-ventricular dysfunction in patients ... as an outcome.: Results: A total of 5 randomized controlled trials met the inclusion criteria, for 2,923 ...

    Abstract Background: Diabetes mellitus is an independent risk factor of increased morbidity and mortality in patients with heart failure. Cardiac resynchronization therapy (CRT), a pacemaker-based therapy for dyssynchronous heart failure, improves cardiac performance and quality of life, but its effect on mortality in patients with diabetes is uncertain.
    Methods: We performed a meta-analysis of results from randomized controlled trials (RCTs) of the long-term outcome of cardiac resynchronization therapy for heart failure in diabetic and non-diabetic patients. Literature search of MEDLINE via Pubmed for reports of randomized controlled trials of Cardiac resynchronization for chronic symptomatic left-ventricular dysfunction in patients with and without diabetes mellitus, with death as the outcome. Relevant data were analyzed by use of a random-effects model. Reports published from 1994 to 2011 that described RCTs of CRT for treating chronic symptomatic left ventricular dysfunction in patients with and without diabetes, with all-cause mortality as an outcome.
    Results: A total of 5 randomized controlled trials met the inclusion criteria, for 2,923 patients. The quality of studies was good to moderate. Cardiac resynchronization significantly reduced the mortality for heart failure patients with or without diabetes mellitus. Mortality was 24.3% for diabetic patients with heart failure and 20.4 % for non-diabetics (odds ratio 1.28, 95% confidence interval 1.06-1.55; P = 0.010).
    Conclusions: Cardiac resynchronization therapy (CRT) may reduce mortality from progressive heart failure in patients with or without diabetes mellitus, but mortality may be higher for patients with than without diabetes after CRT for heart failure.
    MeSH term(s) Cardiac Resynchronization Therapy ; Cause of Death ; Diabetic Cardiomyopathies ; Heart Failure/complications ; Heart Failure/mortality ; Heart Failure/therapy ; Humans ; Quality of Life
    Language English
    Publishing date 2015-03-21
    Publishing country England
    Document type Journal Article ; Meta-Analysis ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2059859-2
    ISSN 1471-2261 ; 1471-2261
    ISSN (online) 1471-2261
    ISSN 1471-2261
    DOI 10.1186/s12872-015-0018-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials.

    Rivero-Ayerza, Máximo / Theuns, Dominic A M J / Garcia-Garcia, Hector M / Boersma, Eric / Simoons, Maarten / Jordaens, Luc J

    European heart journal

    2006  Volume 27, Issue 22, Page(s) 2682–2688

    Abstract: ... HF and a depressed left ventricular systolic performance were selected for this analysis. Trials ... Aims: Cardiac resynchronization therapy (CRT) has been shown to improve symptoms and ... searched. Randomized controlled studies that evaluated the effects of CRT alone in patients with advanced ...

    Abstract Aims: Cardiac resynchronization therapy (CRT) has been shown to improve symptoms and exercise tolerance in patients with advanced heart failure (HF). However, studies were underpowered to address its effect on overall mortality. To evaluate whether CRT alone (without a combined defibrillator function) reduces overall mortality as compared with optimal pharmacological therapy, and how it affects the mode of death in patients with advanced HF.
    Methods and results: Public domain databases were systematically searched. Randomized controlled studies that evaluated the effects of CRT alone in patients with advanced HF and a depressed left ventricular systolic performance were selected for this analysis. Trials, which did not independently report data on CRT alone or had a follow-up period of less than 3 months, were excluded. Five studies were identified and analyzed. They included a total of 2371 patients, 1028 controls and 1343 CRT-treated patients. Pooled analysis demonstrated that CRT alone, as compared with optimal medical therapy, significantly reduced all-cause mortality by 29% [16.9 vs. 20.7%; odds ratio (OR), 0.71; 95% confidence interval (CI), 0.57-0.88] and mortality due to progressive HF by 38% (6.7 vs. 9.7%; OR, 0.62; 95% CI, 0.45-0.84). No effect on sudden cardiac death (SCD) was observed with CRT (6.4 vs. 5.9%; OR, 1.04; 95% CI, 0.73-1.22).
    Conclusions: CRT alone as compared with optimal medical therapy reduces all-cause mortality in patients with advanced HF. It predominantly reduces worsening HF mortality, not affecting SCD.
    MeSH term(s) Aged ; Cardiac Pacing, Artificial/methods ; Cause of Death ; Female ; Heart Failure/mortality ; Heart Failure/therapy ; Humans ; Male ; Middle Aged ; Randomized Controlled Trials as Topic
    Language English
    Publishing date 2006-11
    Publishing country England
    Document type Journal Article ; Meta-Analysis ; Review
    ZDB-ID 603098-1
    ISSN 1522-9645 ; 0195-668X
    ISSN (online) 1522-9645
    ISSN 0195-668X
    DOI 10.1093/eurheartj/ehl203
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top